Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06398613 Recruiting - Prostate Cancer Clinical Trials

Preoperative PSMA PET/CT as Triage for ePLND in Patients Scheduled for RALP (PrePSMA)

PrePSMA
Start date: April 26, 2024
Phase: N/A
Study type: Interventional

Extended pelvic lymph node dissection (ePLND) is considered the gold standard for nodal staging in men with prostate cancer (PCa). The aim of this project is to determine if preoperative prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomograpy (CT) can safely replace ePLND as a staging method in PCa patients undergoing robot-assisted laparoscopic radical prostatectomy (RALP).

NCT ID: NCT06397755 Recruiting - Prostate Cancer Clinical Trials

Observational Study of Patients Who Underwent Diagnostic Investigation (Prostate Biopsy) and/or Radical Prostatectomy Surgery.

Start date: January 8, 2015
Phase:
Study type: Observational

This is a single-center, observational, prospective and retrospective study on quality of life and disease status of patients who underwent prostate biopsy and/or radical prostatectomy.

NCT ID: NCT06397703 Recruiting - Prostate Cancer Clinical Trials

ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer

Start date: April 16, 2024
Phase: Phase 3
Study type: Interventional

For this proposed Phase III study, unfavorable intermediate risk prostate cancer patients will be randomized to receive 6 months of Androgen Deprivation Therapy (ADT) in conjunction with stereotactic body radiation therapy/radiosurgery (SBRT) directed to the prostate versus SBRT alone. The patient population will include those with National Comprehensive Cancer Network (NCCN)-defined unfavorable intermediate risk disease. All patients will be followed every 6 months for up to 5 years from the first patient randomized and will undergo a routine 24-30 months post-SBRT prostate biopsy to assess for local tumor control.

NCT ID: NCT06395519 Recruiting - Breast Cancer Clinical Trials

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

ERADIC8
Start date: May 2024
Phase: Phase 1
Study type: Interventional

This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.

NCT ID: NCT06389695 Recruiting - Prostate Cancer Clinical Trials

Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM032 in Patients

Start date: May 2024
Phase: Phase 1
Study type: Interventional

68Ga-NYM032 is a PSMA-targeting small-molecular radiotracer for PET/CT imaging of prostate cancer, which is needed for clinical trial to be conducted

NCT ID: NCT06385847 Recruiting - Prostate Cancer Clinical Trials

To Assess The Patient Preference for Goserelin Microsphere Versus Goserelin Implant in Patients With Prostate Cancer

Start date: May 2024
Phase: Phase 2
Study type: Interventional

The GOMIMP will be a Prospective, Randomized, Cross-over Trial to Explore the Patient Preference for Goserelin Microsphere (Zoladex®) Versus Goserelin Implant (LY01005) in Patients of Prostate Cancer

NCT ID: NCT06380660 Recruiting - Breast Cancer Clinical Trials

Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors

Start date: March 22, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine if the experimental treatment with poly-ADP ribose polymerase (PARP) inhibitor, ACE-86225106 is safe, tolerable and has anti-cancer activity in adult patients with advanced solid tumors.

NCT ID: NCT06378346 Recruiting - Prostate Cancer Clinical Trials

GU-01: Glycyrrhizin in Prostate Cancer

GU-01
Start date: May 2024
Phase: Phase 2
Study type: Interventional

This is a pilot, randomized, window-of-opportunity treatment trial in which participants with previously untreated prostate cancer (PCa) who are candidates for surgery (radical prostatectomy)

NCT ID: NCT06375629 Recruiting - Prostate Cancer Clinical Trials

ES-HIFU, Prospective Data Collection of Patients Treated With Partial Gland HIFU Ablation for Prostate Cancer

ES-HIFU
Start date: April 20, 2023
Phase:
Study type: Observational

The objective of this study is to evaluate the clinical effectiveness and safety of treatment of prostate cancer in patients who have received a focal HIFU treatment using the Focal One medical device.

NCT ID: NCT06363435 Recruiting - Prostate Cancer Clinical Trials

AI-based Measurements of Tumour Burden in PSMA PET-CT

Start date: March 29, 2024
Phase:
Study type: Observational

The primary aim of the present study is to evaluate how automatically calculated (by an AI-based method) tumour burden, measured as tumour volume (TV) and as tumour uptake (TU: TV x SUVmean) in the prostate/prostate bed, pelvic lymph nodes, distant lymph nodes, bone and as the total tumour burden predicts overall survival (OS) in patients with prostate cancer (newly diagnosed and patients with biochemical recurrence).